Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib

(2019) Paweł Kawalec et al.   Therapeutics and Clinical Risk Management

Clinical significance of Janus Kinase inhibitor selectivity

(2019) Ernest H Choy   RHEUMATOLOGY

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

(2018) Sumit Kunwar et al.   CLINICAL RHEUMATOLOGY

Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials

(2018) Feng Huang et al.   CLINICAL RHEUMATOLOGY

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY